Video
A urologist gives his take on PSMA in prostate cancer
Author(s):
“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.
Video Player is loading.
In this video, Jason M. Hafron, MD, shares why he thinks PSMA is “disruptive technology” in prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan. He was speaking at the 2021 LUGPA annual meeting.
Related Videos
Jason Hafron, MD, considers the future for AI in urology
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
Related Content
